Invivyd (IVVD) Price & Analysis

Compare

571 Followers

IVVD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.35 - $2.74

Previous CloseN/A

Volume606.77K

Average Volume (3M)8.91M

Market Cap

$189.69M

Enterprise Value$53.87M

Total Cash (Recent Filing)$34.91M

Total Debt (Recent Filing)$2.96M

Price to Earnings (P/E)―

Beta1.93

Next Earnings

Nov 12, 2025

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding194,954,210

10 Day Avg. Volume25,232,390

30 Day Avg. Volume8,909,015

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.28

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit1.25

Enterprise Value/Ebitda-0.49

Forecast

1Y Price Target

$5.00

Price Target Upside385.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trials And Regulatory ProgressRegulatory clarity achieved with alignment on a single, randomized, placebo-controlled prevention trial for VYD2311, supporting a potential Biologics License Application.

Commercial PerformanceNet revenue from PEMGARDA rose 48% sequentially in 4Q24, reflecting growing prescriber adoption and renewed confidence.

Vaccine Access PolicyEmerging policy discussions suggest potential U.S. vaccine access changes that could favor long-acting prophylactic antibodies.

Bears Say

Launch PerformanceThe initial launch trajectory of PEMGARDA fell short of expectations, leading to a lowered price target.

Market RisksA 75% risk adjustment is included on the COVID-19 prophylaxis franchise, capturing risks tied to emerging COVID-19 variants and potential delays in antibody approvals.

Invivyd News

Invivyd 50M share Spot Secondary priced at 52c

Cantor Fitzgerald acted as sole book running manager for the offering. Published first on TheFly – the ultimate...

14d ago

IVVD

Closing Bell Movers: Nordson up 5% after Q3 earnings beat

In the opening hour of the evening session, U.S. equity futures are little changed following more losses in...

14d ago

Invivyd announces common stock offering, no amount given

Invivyd (IVVD) announced that it has commenced an underwritten public offering of shares of its common stock. Invivyd...

15d ago

IVVD

Invivyd says PEMGARDA effective against XFG variant of SARS-CoV-2

Invivyd (IVVD) announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA against the currently dominant and...

17d ago

IVVD

Invivyd aligns with FDA on pathway to approval of COVID-19 vaccine VYD2311

Invivyd (IVVD) has received and is aligned with advice from the FDA on a compact and, therefore, rapid...

21d ago

IVVD

Invivyd’s Promising Position in the Antibody Market: Buy Rating Supported by Strong Data and Financial Growth

Invivyd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C....

8d ago

IVVD

Invivyd Raises $53.5 Million in Public Offering

Invivyd ( ($IVVD) ) has shared an update. On August 20, 2025, Invivyd, Inc. entered into an underwriting...

13d ago

IVVD

Invivyd Reports Strong Revenue Growth Amid Strategic Advances

Invivyd ( ($IVVD) ) has released its Q2 earnings. Here is a breakdown of the information Invivyd presented...

14d ago

IVVD

Invivyd’s Transformative Year: Regulatory Advances and Market Potential Drive Buy Rating

Invivyd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C....

17d ago

IVVD

Invivyd Aligns with FDA for Rapid Approval Pathway

Invivyd ( ($IVVD) ) just unveiled an update. On August 14, 2025, Invivyd announced its alignment with the...

21d ago

IVVD

Invivyd announces addition of Iwasaki to SPEAR Study Group

Invivyd (IVVD) announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to...

1M ago

IVVD

Invivyd announces updated NCCN Clinical Practice Guidelines for COVID-19

Invivyd (IVVD) announced the June 20, 2025 updated National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology...

1M ago

IVVD

Invivyd Launches SPEAR Study for Long COVID Therapy

Invivyd ( ($IVVD) ) has shared an announcement. On July 2, 2025, Invivyd announced the formation of the...

2M ago

IVVD

Invivyd forms SPEAR study group to assess therapy for long-COVID

Invivyd (IVVD) announced that it has formed a clinical and translational study group, the SPEAR Study Group, with...

2M ago

IVVD

IVVD FAQ

What was Invivyd’s price range in the past 12 months?

Invivyd lowest stock price was $0.35 and its highest was $2.74 in the past 12 months.

What is Invivyd’s market cap?

Invivyd’s market cap is $189.69M.

When is Invivyd’s upcoming earnings report date?

Invivyd’s upcoming earnings report date is Nov 12, 2025 which is in 69 days.

How were Invivyd’s earnings last quarter?

Invivyd released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.116.

Is Invivyd overvalued?

According to Wall Street analysts Invivyd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Invivyd pay dividends?

Invivyd does not currently pay dividends.

What is Invivyd’s EPS estimate?

Invivyd’s EPS estimate is -0.07.

How many shares outstanding does Invivyd have?

Invivyd has 194,954,210 shares outstanding.

What happened to Invivyd’s price movement after its last earnings report?

Invivyd reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went down -11.25%.

Which hedge fund is a major shareholder of Invivyd?

Currently, no hedge funds are holding shares in IVVD

Invivyd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-120.08%

Trailing 12-Months

Asset Growth

-49.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Invivyd

Invivyd, Inc. (IVVD) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases. The company's core products include monoclonal antibodies designed to treat and prevent viral infections, with a particular emphasis on addressing unmet medical needs in the field of infectious disease prevention and treatment.

Invivyd (IVVD) Earnings & Revenues

Historic Earnings Reports

IVVD Company Deck

IVVD Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a strategic shift towards internalization and pipeline expansion, with promising early indicators and additional capital access. However, challenges with Q1 revenue and regulatory hurdles for EUA expansion tempered the outlook.View all IVVD earnings summaries

IVVD Stock 12 Month Forecast

Average Price Target

$5.00

▲(385.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.0584615384615383,1.3869230769230767,1.7153846153846153,2.043846153846154,2.3723076923076922,2.7007692307692306,3.029230769230769,3.3576923076923073,3.6861538461538457,4.014615384615384,4.343076923076922,4.671538461538461,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.0584615384615383,1.3869230769230767,1.7153846153846153,2.043846153846154,2.3723076923076922,2.7007692307692306,3.029230769230769,3.3576923076923073,3.6861538461538457,4.014615384615384,4.343076923076922,4.671538461538461,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.73,1.0584615384615383,1.3869230769230767,1.7153846153846153,2.043846153846154,2.3723076923076922,2.7007692307692306,3.029230769230769,3.3576923076923073,3.6861538461538457,4.014615384615384,4.343076923076922,4.671538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >